2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1011

Structural Damage Is Reduced by Early Achievement of Clinical Remission
Abstract Number: 591

Structural Progression of Ankylosing Spondylitis Associated with Elevation in Two NOVEL, Inflammatory Biomarkers; Matrix Metalloproteinase and Cathepsin-Derived
Abstract Number: 2130

Studies of Disease and Therapy-Response Biomarkers in Early Rheumatoid Arthritis Treated with Methotrexate
Abstract Number: 641

Study of Anti-Müllerian Hormone and Probability of Pregnancy in 112 Systemic Lupus Erythematosus Patients Exposed or Not to Cyclophosphamide
Abstract Number: 1205

Study of Association of CD40-CD154 Gene Polymorphisms with Disease Susceptibility and Cardiovascular Risk in Spanish Rheumatoid Arthritis Patients
Abstract Number: 1473

Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis
Abstract Number: 131

Subclinical Arthritis Visualised by Positron Emission Tomography and Macrophage Targeting Precedes Clinical Flare in Rheumatoid Arthritis Patients in DAS28 Remission
Abstract Number: 1257

Subclinical Atherosclerosis in Hispanic Patients with Rheumatoid Arthritis. Correlation with the Presence of Anti-Oxidized LDL Antibodies and Serum Levels of CD40L
Abstract Number: 462

Subcutaneous Abatacept: Long-Term Data From the Acquire Trial
Abstract Number: 829

Subcutaneous Nodules Are Significantly Associated with Cardiovascular Events in Patients with Rheumatoid Arthritis: Results From a Very Large US Registry
Abstract Number: 83

Substantial Functional Disability Is the Key Determinant of Discrepancies Between EQ-5D and SF-6D Utility Measures in Early Arthritis: Results From the Espoir Cohort
Abstract Number: 2379

Successful Treatment of Churg-Strauss Syndrome with Rituximab
Abstract Number: 651

Suicidal Ideation in Patients with Systemic Lupus Erythematosus: Incidence and Relationship with Anxiety/Depression Score Disease Activity and Organ Damage
Abstract Number: 2320

Superantigen Induces IL-17 Production From Extremely Polarized Th1 Clones
Abstract Number: 8

Supercharged Sox9 Protein Induces Chondrogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].